文献速递胸部肿瘤放疗

III-N2期肺淋巴上皮瘤样癌的治疗选择:一项回顾性队列研究

Treatment options for stage III-N2 pulmonary lymphoepithelioma-like carcinoma: A retrospective cohort study.
PubMed 文献 · Radiother Oncol · 2023-10-04

该回顾性队列研究纳入2009至2022年单中心103例III-N2期肺淋巴上皮瘤样癌患者,分为根治性放化疗组(G1,34例)、根治性手术联合辅助放化疗组(G2,25例)和根治性手术联合辅助化疗组(G3,44例)。中位随访47.4个月,全组中位无进展生存期(PFS)66.6个月,3年PFS率66.0%、3年总生存(OS)率92.4%。多因素分析显示G1与G2的PFS无显著差异(p=0.354),但两组PFS均显著长于G3(p<0.001;p=0.039);OS方面G1与G2无显著差异(p=0.649),两组较G3均有改善趋势(p=0.081;p=0.092)。

要点

  • III-N2期肺淋巴上皮瘤样癌患者预后较好,放疗在治疗中起关键作用。
  • 根治性放化疗与根治性手术联合辅助放化疗疗效均较好且毒性可控。
  • 根治性放化疗与手术联合辅助放化疗的PFS和OS均无显著差异。

核心结论

  • III-N2期肺淋巴上皮瘤样癌患者预后较好,放疗在治疗中起关键作用;根治性放化疗与根治性手术联合辅助放化疗均显示出较好疗效且毒性可控。

研究设计与样本

  • 本研究为单中心回顾性分析,纳入2009年至2022年该中心III-N2期肺淋巴上皮瘤样癌患者,共103例,分为G1根治性放化疗组34例、G2根治性手术联合辅助放化疗组25例、G3根治性手术联合辅助化疗组44例。

主要发现

  • 全组中位随访47.4个月,中位PFS为66.6个月,3年PFS率为66.0%,3年OS率为92.4%。
  • 多因素分析显示G1与G2的PFS无显著差异(p=0.354),G1与G2的PFS均显著长于G3(p<0.001;p=0.039)。
  • G1与G2的OS无显著差异(p=0.649),G1与G2较G3的OS均有改善趋势(p=0.081;p=0.092)。
  • G1仅观察到1例3级放射性食管炎,未报告3级及以上放射性肺炎。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare form of non-small cell lung carcinoma (NSCLC) that shares similarities with nasopharyngeal carcinoma. The optimal treatment for stage III-N2 PLELC remains controversial. METHODS AND MATERIALS: We conducted a retrospective analysis from stage III-N2 PLELC patients between 2009 and 2022 in our center. The patients were categorized into three groups: Group 1 (G1, definitive chemoradiotherapy), Group 2 (G2, radical surgery plus adjuvant chemoradiotherapy), and Group 3 (G3, radical surgery plus adjuvant chemotherapy). RESULTS: A total of 103 patients were included in the study, with 34, 25, and 44 patients in G1, G2, and G3, respectively. The median follow-up time was 47.4 months. The overall median PFS was 66.6 months, with 3-year PFS and 3-year OS rates of 66.0% and 92.4%, respectively, for all patients. Multivariate analysis revealed no significant difference in PFS between G1 and G2 (p = 0.354), while both groups exhibited significantly longer PFS than G3 (p < 0.001; p = 0.039). Similarly, no significant difference in OS was observed between G1 and G2 (p = 0.649), but both tended to demonstrate improved OS compared to G3 (p = 0.081; p = 0.092). Only one case of grade 3 radiation esophagitis was observed in G1, and no grade 3 or higher radiation pneumonitis were reported. CONCLUSIONS: Patients with stage III-N2 PLELC have a favorable prognosis, with radiotherapy playing a crucial role in treatment. Both definitive chemoradiotherapy and radical surgery followed by chemoradiotherapy demonstrate favorable efficacy and manageable toxicity.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Hou Z, Guo Y, Shen X, et al. Treatment options for stage III-N2 pulmonary lymphoepithelioma-like carcinoma: A retrospective cohort study. Radiother Oncol. 2023. PMID: 37797658. doi:10.1016/j.radonc.2023.109937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。